Navigation Links
Global Pharm Holdings Group Announces First Quarter 2011 Financial Results
Date:5/16/2011

paid-in capital

9,200,623

9,200,623Statutory surplus reserves

1,310,701

1,310,701Retained earnings

11,837,920

6,546,406Accumulated other comprehensive income

693,492

544,434Total stockholders' equity

23,068,736

17,628,164Total liabilities and stockholders' equity

$51,328,705$43,177,453GLOBAL PHARM HOLDINGS GROUP, INC.CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME(Unaudited)Three months ended March 31,20112010Revenues, net$42,120,757$28,892,870Cost of goods sold34,296,10623,777,194Gross profit7,824,6515,115,676Expenses:Operating expenses419,050167,570General and administrative733,019302,783Income from operations6,672,5824,645,323Interest (expense) income (4,147)5,915Miscellaneous expense(1,874)-Income before income taxes6,666,5614,651,238Provision for income taxes1,375,0471,161,722Net income5,291,5143,489,516Other comprehensive income   Foreign currency translation adjustment149,058(812)Total comprehensive income$5,440,572$3,488,704Earnings per share of common stock:Basic and diluted earnings per share$0.20$0.18Basic and diluted weighted average shares26,000,00019,094,000GLOBAL PHARM HOLDINGS GROUP, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) Three months ended March 31, 20112010Cash flows from operating activitiesNet Income$5,291,514$3,489,516Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization18,89416,975Changes in operating assets and liabilities:Accounts receivable(3,215,411)(2,522,535)Inventories(1,569,016)(2,520,577)Restricted cash1,173,196-Other current assets383,506(1,685,213)Accounts payable and other accrued liabilities3,657,5964,011,196Other taxes payable(290,947)329,736Due to related party312,770(928,148)Net cash provided by operating activities5,762,102190,950Cash flows from investing activitiesPurchase of property, plant and equipment(45,560)(9,092)Cash flows from financin
'/>"/>

SOURCE Global Pharm Holdings Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
3. Directors Forum: PEPFAR and the Global AIDS Response
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
9. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Medical devices are ... a biological product. In light of their different mechanisms, ... are much more complicated than drug trails due to ... MD safety instead of evaluating both safety and efficacy ... FDA (which is the same as the SFDA) evaluate ...
(Date:5/17/2013)... SAN DIEGO and CAMBRIDGE, Mass., May 17, 2013 ... announce that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: ... District Court for the District of Massachusetts ... of its officers violated the Securities Exchange Act of ... May 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)...  TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...
Breaking Medicine Technology:Statistical Challenges in Medical Device Trail Evaluation 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2
... Eli Lilly and Company,(NYSE: LLY ) ... with the,European Medicines Agency (EMEA) for centralised review ... for the,first-line treatment of advanced non-small cell lung ... more than 85 countries as a,second-line, single agent ...
... insulin glargine, exenatide offered added benefits of, ... with metformin --, AMSTERDAM, Netherlands, Sept. 21 ... Eli Lilly and Company (NYSE: LLY ),today ... insulin glargine on beta-cell function, glycemic control and ...
Cached Medicine Technology:Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 2Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 3Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 4Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 5Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 6Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 7Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 8Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 9Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 10Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 11Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 12One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 2One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 3One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 4One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 5One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 6One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 7
(Date:5/20/2013)... WA (PRWEB) May 20, 2013 6Webs.com ... home alarm system reviews . 6Webs.com recently completed their ... the nation. Reviews are completed annually and the top ... factors which include their monitoring technology, equipment and warranties ... 6Webs.com stated, "When the 6Webs.com team completed the home ...
(Date:5/20/2013)... News) -- Dermatologists are saying that new federally ... make smarter choices when it comes to products ... new labels required by the U.S. Food and ... a sunscreen will protect against skin cancer in ... indicate whether a sunscreen is water-resistant, according to ...
(Date:5/20/2013)... Irving, Texas (PRWEB) May 20, 2013 ... and Phytel, the leader in automated, provider-led population ... health systems to effect change and successfully pursue ... of advisory services and technology to accelerate the ... of the VHA IMPERATIVTM performance improvement suite of ...
(Date:5/20/2013)... University in Sweden have mapped the significance of ... studies have previously examined whether different forms of ... coronary heart disease, ischemic stroke, peripheral arterial disease ... siblings and parents have suffered different types of ... is highest for atherosclerosis of the aorta followed ...
(Date:5/20/2013)... 20, 2013 Gilman Law LLP, a ... investigating Byetta lawsuits, is troubled by a new study ... and similar type 2 diabetes drugs are growing. ... Practices (ISMP), found that 71 Byetta pancreatic cancer reports ... Administration (FDA) as of June 30, 2012. ...
Breaking Medicine News(10 mins):Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2Health News:Revised Sunscreen Labels Should Help Consumers Make Wiser Choices 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 2Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 3
... , FRIDAY, Nov. 11 (HealthDay News) -- Vaccination ... type b (Hib) among young children in the United States ... That strain of flu was once the most common cause ... mid-1980s. But the researchers also found that other strains ...
... (November 11, 2011) Children treated at home for severe ... recover than children referred to health facilities, Save the Children ... Lancet medical journal today. The results come the ... world,s attention on the leading cause of child death. ...
... University of Michigan researchers will provide genetic testing and ... mild cognitive impairment. Researchers hope to ... caregivers respond to health education and genetic testing, says ... Behavior and Health Education at the U-M School of ...
... NOVEMBER 10, 2011 Results of the PARTNER ... replacement (TAVR) results in improved quality of life compared ... the transfemoral approach. The results of the study were ... (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. ...
... between the ages of 18 and 25 report the highest ... Survey on Drug Use & Health. A new study from ... in prosocial behaviors, such as volunteering and helping others, are ... Carlo, Millsap Professor of Diversity in the Department of Human ...
... Foundation (AHAF), a nonprofit organization funding innovative research through ... the number of scientists seeking ADR research grants through ... "It,s a sign of difficult times for the ... Guy Eakin, Ph.D. "Finding government funding is tough ...
Cached Medicine News:Health News:Lancet pneumonia study offers new hope for reducing No. 1 cause of child death 2Health News:Lancet pneumonia study offers new hope for reducing No. 1 cause of child death 3Health News:Quality of life benefits of transcatheter aortic valve replacement differ by access site 2Health News:Volunteering, helping others decreases substance use in rural teens, MU study finds 2Health News:Requests for Alzheimer's disease research grants up by 33 percent, as federal funding in doubt 2Health News:Requests for Alzheimer's disease research grants up by 33 percent, as federal funding in doubt 3
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: